BioSpace News Archive

Zynex, Inc today announced preliminary results for first quarter 2022, affirming guidance for revenue, EBITDA and order growth.

Microbix Biosystems Inc. announces it will present performance results of its Quality Assessment Products (“ QAPs™ ”) supporting Human Papillomavirus (“ HPV ”) molecular-diagnostic screening-tests at the 2022 annual congress of the European Research Organization on Genital Infection and Neoplasia (“ EUROGIN ”) taking place in Düsseldorf, Germany from April 10=12, 2022.

Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9 , before the open of the U.S. financial markets.

Orthofix Medical Inc today announced a leadership transition for its Orthopedics Business Unit. Kimberley Elting, currently Chief Legal and Development Officer for Orthofix, will become the President of the Global Orthopedics Business.

BeiGene today announced that clinical results, as well as biomarker data, from its immuno-oncology program in solid tumors will be presented at the American Academy for Cancer Research (AACR) Annual Meeting 2022.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced changes to its Board of Directors. L. Patrick Gage, Ph.D., Chairman of the Board of Directors since March 2010, will resign from the Board effective April 8, 2022.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022.

Novavax, Inc. and Serum Institute of India Pvt. Ltd. announced that the Thailand Food and Drug Administration has granted emergency use authorization for Novavax’ protein-based vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in individuals 18 years of age and older.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced new preclinical data highlighting the potent anti-tumor efficacy of the next-generation BiSKIT, anti-PD1-MDNA109FEAA, in an electronic poster at the American Association for Cancer Research Annual Meeting.

Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights.